Your browser doesn't support javascript.
loading
Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas-an ENITEC Group Initiative.
Cuppens, Tine; Annibali, Daniela; Coosemans, An; Trovik, Jone; Ter Haar, Natalja; Colas, Eva; Garcia-Jimenez, Angel; Van de Vijver, Koen; Kruitwagen, Roy P M; Brinkhuis, Mariël; Zikan, Michal; Dundr, Pavel; Huvila, Jutta; Carpén, Olli; Haybaeck, Johannes; Moinfar, Farid; Salvesen, Helga B; Stukan, Maciej; Mestdagh, Carole; Zweemer, Ronald P; Massuger, Leonardus F; Mallmann, Michael R; Wardelmann, Eva; Mints, Miriam; Verbist, Godelieve; Thomas, Debby; Gommé, Ellen; Hermans, Els; Moerman, Philippe; Bosse, Tjalling; Amant, Frédéric.
Afiliación
  • Cuppens T; Department of Oncology, Gynecologic Oncology, KU Leuven (University of Leuven), Leuven, Belgium.
  • Annibali D; Department of Oncology, Gynecologic Oncology, KU Leuven (University of Leuven), Leuven, Belgium.
  • Coosemans A; Department of Oncology, Laboratory of Tumor Immunology and Immunotherapy, ImmunOvar Research Group, KU Leuven (University of Leuven), Leuven, Belgium.
  • Trovik J; Department of Gynaecology and Obstetrics, Leuven Cancer Institute, UZ Leuven, Leuven, Belgium.
  • Ter Haar N; Department of Gynecology and Obstetrics, Haukeland University Hospital, Bergen, Norway.
  • Colas E; Department of Clinical Science, Centre for Cancer Biomarkers, University of Bergen, Bergen, Norway.
  • Garcia-Jimenez A; Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands.
  • Van de Vijver K; Biomedical Research Group in Gynecology, Vall d'Hebron Institute of Research (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Kruitwagen RP; Department of Pathology and Molecular Genetics/Oncologic Pathology Group, Arnau de Vilanova University Hospital, University of Lleida, IRB Lleida, Lleida, Spain.
  • Brinkhuis M; Department of Pathology, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Zikan M; Department of Pathology, GROW - School for Oncology & Developmental Biology, Maastricht University Medical Centre, the Netherlands.
  • Dundr P; Department of Gynecology and Obstetrics, GROW - School for Oncology & Developmental Biology, Maastricht University Medical Centre, Maastricht, the Netherlands.
  • Huvila J; Laboratory for Pathology Oost Nederland, Hengelo, The Netherlands.
  • Carpén O; Department of Obstetrics and Gynecology, Gynecological Oncology Center, Charles University in Prague - 1st Faculty of Medicine and General University Hospital in Prague, Czech Republic.
  • Haybaeck J; Department of Pathology, Charles University in Prague - 1st Faculty of Medicine and General University Hospital in Prague, Prague, Czech Republic.
  • Moinfar F; Department of Pathology, University of Turku and Turku University Hospital, Turku, Finland.
  • Salvesen HB; Department of Pathology, University of Turku and Turku University Hospital, Turku, Finland.
  • Stukan M; Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
  • Mestdagh C; Institute of Pathology, Medical University of Graz, Graz, Austria.
  • Zweemer RP; Department of Pathology, Hospital of the Sisters of Charity, Linz, Austria.
  • Massuger LF; Department of Gynecology and Obstetrics, Haukeland University Hospital, Bergen, Norway.
  • Mallmann MR; Department of Clinical Science, Centre for Cancer Biomarkers, University of Bergen, Bergen, Norway.
  • Wardelmann E; Department of Gynecologic Oncology, Oncology Center, Provincial Hospitals Gdynia, Gdynia, Poland.
  • Mints M; Institut de Pathologie et de Génétique, Brussels, Belgium.
  • Verbist G; Department of Gynecological Oncology, UMC Utrecht Cancer Center, Utrecht, the Netherlands.
  • Thomas D; Department of Obstetrics and Gynecology, Radboud University Medical Centre Nijmegen, Nijmegen, the Netherlands.
  • Gommé E; Department of Obstetrics and Gynecology, University of Bonn, Bonn, Germany.
  • Hermans E; Institute of Pathology, University Hospital Cologne, Cologne, Germany.
  • Moerman P; Department of Women's and Children's Health, Karolinska Institutet at Karolinska University Hospital Solna, Stockholm, Sweden.
  • Bosse T; Department of Development and Regeneration, KU Leuven (University of Leuven), Leuven, Belgium.
  • Amant F; Department of Oncology, Trace Platform, KU Leuven (University of Leuven) - UZ Leuven, Leuven, Belgium.
Clin Cancer Res ; 23(5): 1274-1285, 2017 Mar 01.
Article en En | MEDLINE | ID: mdl-28232476
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Uterinas / Proteína S6 Ribosómica / Serina-Treonina Quinasas TOR / Leiomiosarcoma Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2017 Tipo del documento: Article País de afiliación: Bélgica Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Uterinas / Proteína S6 Ribosómica / Serina-Treonina Quinasas TOR / Leiomiosarcoma Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2017 Tipo del documento: Article País de afiliación: Bélgica Pais de publicación: Estados Unidos